NCEL logo

NCEL
NewcelX Ltd.

6,135
Mkt Cap
$10.95M
Volume
82,217.00
52W High
$33.70
52W Low
$1.89
PE Ratio
-0.14
NCEL Fundamentals
Price
$2.48
Prev Close
$2.36
Open
$2.45
50D MA
$3.05
Beta
0.54
Avg. Volume
89,510.14
EPS (Annual)
-$26.29
P/B
0.37
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression...
PR Newswire·9d ago
News Placeholder
More News
News Placeholder
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes...
PR Newswire·16d ago
News Placeholder
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in...
PR Newswire·1mo ago
News Placeholder
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute NewcelX Strengthens Scientific Advisory Board...
PR Newswire·2mo ago
News Placeholder
NewcelX CEO Issues Letter to Shareholders
NewcelX CEO Issues Letter to Shareholders NewcelX CEO Issues Letter to Shareholders PR Newswire ZURICH, Nov. 4, 2025 ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss...
PR Newswire·3mo ago
News Placeholder
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire ZURICH and NESS ZIONA, Israel, Oct. 30...
PR Newswire·3mo ago
<
...
1
>

Latest NCEL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.